Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Other Operating Expenses: 2019-2025

Historic Other Operating Expenses for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $4.1 million.

  • Biodesix's Other Operating Expenses fell 1.58% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 11.02%. This contributed to the annual value of $15.8 million for FY2024, which is 21.12% up from last year.
  • Biodesix's Other Operating Expenses amounted to $4.1 million in Q3 2025, which was up 1.38% from $4.1 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Other Operating Expenses registered a high of $19.2 million during Q1 2021, and its lowest value of $2.5 million during Q4 2021.
  • For the 3-year period, Biodesix's Other Operating Expenses averaged around $3.7 million, with its median value being $3.8 million (2025).
  • The largest annual percentage gain for Biodesix's Other Operating Expenses in the last 5 years was 742.31% (2021), contrasted with its biggest fall of 82.82% (2021).
  • Quarterly analysis of 5 years shows Biodesix's Other Operating Expenses stood at $2.5 million in 2021, then soared by 32.61% to $3.3 million in 2022, then climbed by 2.78% to $3.4 million in 2023, then spiked by 30.81% to $4.4 million in 2024, then decreased by 1.58% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $4.1 million for Q2 2025, and $3.8 million during Q1 2025.